[August 12, 2015]

Research and Markets: European Automated Microbiology Market 2015-2019 - Examines Key Trends in the Major European Countries

Research and Markets (http://www.researchandmarkets.com/research/sfzps6/20152019) has announced the addition of the "2015-2019 European Automated Microbiology Market: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics--Emerging Opportunities for Instrument and Reagent Suppliers--Competitive" report to their offering.

2015-2019 European Automated Microbiology Market is a new five-country strategic analysis of major business opportunities emerging in the automated microbiology market during the next five years. The report examines key trends in the major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; an suggests alternative business expansion strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans.

The companies analyzed in the report include

• Abbott,
  
• Affymetrix,
  
• Agilent (News - Alert) Technologies,
• Arca Biopharma,
  
• Beckman Coulter/Danaher,
  
• Becton Dickinson,
  
• Biokit,
  
• bioMerieux,
• Bio-Rad,
• Biotest,
  
• Cepheid,
  
• CellMark
  
• Forensics/LabCorp,
  
• Decode Genetics,
  
• Diadexus,
  
• Diamedix,
  
• DiaSorin,
  
• Eiken Chemical,
• Elitech Group,
  
• Enzo Biochem,
  
• Exact Sciences,
  
• Fujirebio, Grifols,
• Hologic/Gen-Probe,
  
• Illumina,
• ID Biomedical/GSK,
  
• Kreatech
• Leica,
• Li-Cor Biosciences,
  
• Lonza,
  
• Monogram Biosciences,
  
• Myriad Genetics,
  
• Ortho-Clinical Diagnostics,
• Perkin Elmer/Caliper,
  

For more information visit http://www.researchandmarkets.com/research/sfzps6/20152019.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150812005863/en/

[ Back To TMCnet.com's Homepage ]